To investigate this potential concern, the researchers conducted a retrospective cohort study involving 139,002 older adults with diabetes, drawn from administrative health databases in Ontario. The data, covering three years from January 2020 to November 2023, were sourced from the Institute for Clinical Evaluative Sciences. Patients included in the study were aged 66 years or older, had a diagnosis of diabetes, and had not been previously diagnosed with nAMD. The team matched 46,334 GLP-1 RA users to 92,668 non-users, ensuring comparable demographics and comorbidities using propensity score matching.
The primary objective was to assess the incidence and timing of new nAMD diagnoses among those exposed to GLP-1 RAs for at least six months.
The study revealed the following findings:
- Patients using GLP-1 receptor agonists had more than double the risk of developing neovascular age-related macular degeneration (nAMD) compared to non-users.
- The crude hazard ratio for nAMD development was 2.11.
- The adjusted hazard ratio remained high at 2.21.
- Despite the relative risk increase, the absolute difference in nAMD incidence was only 0.1%.
- These findings highlight potential safety concerns, especially for older individuals already at higher risk for age-related eye disorders.
- Although the number of new nAMD cases was small, the observed statistical association calls for further investigation.
“This study highlights a possible link between systemic GLP-1 RA use and retinal changes leading to nAMD. As these medications become more common in chronic disease management, their long-term effects on the eye must be better understood,” the authors noted.
The study authors also stressed the need for balanced clinical judgment. The benefits of GLP-1 RAs in glucose regulation and weight control are well-established, and abrupt discontinuation is not advised. However, clinicians may consider monitoring for early signs of retinal changes in high-risk patients, particularly older adults with a family history of macular degeneration.
The authors concluded, "While the increased risk of nAMD remains relatively low in absolute terms, the findings underscore the importance of vigilant, personalized care when prescribing GLP-1 RAs. Additional studies are needed to explore the biological mechanisms underlying this association and determine whether specific patient populations are more vulnerable to ocular side effects."
Reference:
Shor R, Mihalache A, Noori A, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. Published online June 05, 2025. doi:10.1001/jamaophthalmol.2025.1455
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.